RheumMadness Podcast

5.4 Cytokine Crushers

RheumMadness Season 5 Episode 4

In this episode, we are joined by Michael Macklin, MD, PharmD, Assistant Professor of Medicine at the University of Chicago, to discuss the teams in the Cytokine Crushers region of RheumMadness 2025, the Innovation Invitational.

This is part 1 of the conversation, where we go in depth about the long-term outcomes of anifrolumab in SLE study and give a primer about type 1/2 cytokines so you're ready to dig into the TYK2 in SLE and Oral Anti-IL23 studies.

Join us again next week for part 2 of this discussion to learn more about this region.

Links to the Cytokine Crushers Scouting Reports:

Links to old scouting reports and other studies referenced in this podcast:


To learn more about RheumMadness:
https://sites.duke.edu/rheummadness/

Subscribe to our newsletter:
https://lists.duke.edu/sympa/subscribe/rheummadness

Find us on social media:
Bluesky: @rheummadness.bsky.social
Instagram: https://www.instagram.com/rheummadness/
X: Follow #RheumMadness


Intro/outro music: Cheery Monday by Kevin MacLeod
Link: https://incompetech.filmmusic.io/song/3495-cheery-monday
License: http://creativecommons.org/licenses/by/4.0/